Catalog Home Page

Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy

Abed, A., Khattak, A., Millward, M., Chopra, A. and Gray, E. (2019) Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy. Asia-Pacific Journal of Clinical Oncology, 15 (S9). pp. 161-162.

Link to Published Version: https://doi.org/10.1111/ajco.13263
*Subscription may be required

Abstract

Background: We aimed to assess the role of genomic HLA‐I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non‐small lung cancer treated by PD1/L1 inhibitors...

Item Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: John Wiley and Sons
Copyright: © 2019 John Wiley & Sons Australia, Ltd.
Other Information: Special Issue: COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, 12–14 November 2019, Adelaide Convention Centre, South Australia
URI: http://researchrepository.murdoch.edu.au/id/eprint/53129
Item Control Page Item Control Page